Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Ariel Finkelstein, Sabina Izraelov, Arie Roth, Sigal Ben-Shmuel, Gad Keren, Hylton Miller, Jacob George

Research output: Contribution to journalReview articlepeer-review

Abstract

Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.

Original languageEnglish
Pages (from-to)107-109
Number of pages3
JournalInternational Journal of Cardiovascular Interventions
Volume6
Issue number3-4
DOIs
StatePublished - 2004

Keywords

  • Eptifibatide
  • Immune system
  • Lymphocyte activation

Fingerprint

Dive into the research topics of 'Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty'. Together they form a unique fingerprint.

Cite this